Search

Displaying results 6221 - 6230 of 10000 in total
  1. Drug

    Dapoxetine

    go.drugbank.com/drugs/DB04884
    Investigational

    In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo. … In October 2005, the company received a FDA Non-Approvable letter from the FDA, at which time they planned to work with regulators to address outstanding questions.

  2. Drug

    Furvina

    go.drugbank.com/drugs/DB16547
    Experimental

    Furvina is marketed in Cuba as Dermofural®, an ointment containing G1 as the only active principle ingredient. It is used to treat dermatological infections.[A228063] … Furvina (G1) is an antimicrobial agent active against Gram-positive and Gram-negative bacteria, yeasts, and filamentous fungi.

  3. Drug

    Clobetasone

    go.drugbank.com/drugs/DB13158
    Approved

    Clobetasone is a corticosteroid that is often employed topically as a treatment for a variety of conditions such as eczema, psoriasis, various forms of dermatitis, and also for certain ophthalmologic conditions

    Products: U-CLOSONE CREAM, U-CLOSONE OINTMENT
  4. Drug

    Teclozan

    go.drugbank.com/drugs/DB13205
    Investigational

    Teclozan is an antiprotozoal agent employed typically as a therapy to treat protozoan infections.

  5. Drug

    Amrubicin

    go.drugbank.com/drugs/DB06263
    Investigational

    Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. … Since January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer

  6. Drug

    Depreotide

    go.drugbank.com/drugs/DB11628
    ApprovedWithdrawn

    Depreotide is an ingredient in the EMA-withdrawn product NeoSpect.

  7. Drug

    Aminomethylbenzoic acid

    go.drugbank.com/drugs/DB13244
    Experimental

    Aminomethylbenzoic acid may be useful as an antifibrinolytic agent [A174994].

  8. Drug

    AMG 108

    go.drugbank.com/drugs/DB05545
    Investigational

    AMG 108 was investigated for use as an antirheumatic agent.

  9. Drug

    DDP-200

    go.drugbank.com/drugs/DB05919
    Experimental

    DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia.

  10. Drug

    Candoxatril

    go.drugbank.com/drugs/DB00616
    Experimental

    Candoxatril is the orally-active prodrug of candoxatrilat (UK-73967), a potent neutral endopeptidase (NEP) inhibitor.